Drug Profile
PRO 04
Alternative Names: PRO-04Latest Information Update: 16 Oct 2023
Price :
$50
*
At a glance
- Originator Prothix
- Class Monoclonal antibodies
- Mechanism of Action Bradykinin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Angioedema
Most Recent Events
- 16 Oct 2023 Discontinued - Preclinical for Angioedema in Netherlands (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Angioedema in Netherlands
- 20 Jul 2016 PRO 04 is available for licensing - http://prothix.com/strategy/